- Home
- CB vs VCEL Comparison
CB vs VCEL Comparison
Compare CB & VCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CB | VCEL |
|---|---|---|
| Founded | 1985 | 1989 |
| Country | Switzerland | United States |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 106.9B | 2.0B |
| IPO Year | 1993 | 1997 |
Fundamental Metrics
Financial Performance| Metric | CB | VCEL |
|---|---|---|
| Price | $312.25 | $36.47 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 17 | 6 |
| Target Price | ★ $309.06 | $60.40 |
| AVG Volume (30 Days) | ★ 1.8M | 592.9K |
| Earning Date | 01-27-2026 | 11-06-2025 |
| Dividend Yield | ★ 1.26% | N/A |
| EPS Growth | N/A | ★ 236.54 |
| EPS | ★ 23.94 | 0.25 |
| Revenue | ★ $58,842,000,000.00 | $258,716,999.00 |
| Revenue This Year | N/A | $17.86 |
| Revenue Next Year | $5.28 | $18.55 |
| P/E Ratio | ★ $12.89 | $148.09 |
| Revenue Growth | 7.43 | ★ 14.05 |
| 52 Week Low | $252.16 | $29.24 |
| 52 Week High | $308.98 | $63.00 |
Technical Indicators
Market Signals| Indicator | CB | VCEL |
|---|---|---|
| Relative Strength Index (RSI) | 72.96 | 44.40 |
| Support Level | $295.10 | $35.85 |
| Resistance Level | $297.75 | $42.68 |
| Average True Range (ATR) | 4.61 | 1.54 |
| MACD | 1.05 | -0.34 |
| Stochastic Oscillator | 97.88 | 9.01 |
Price Performance
Historical ComparisonAbout CB Chubb Limited
ACE acquired Chubb in the first quarter of 2016 and assumed the Chubb name. The combination made the new Chubb one of the largest domestic property and casualty insurers, with operations in 54 countries spanning commercial and personal P&C insurance, reinsurance, and life insurance.
About VCEL Vericel Corporation
Vericel Corp is a fully integrated, commercial-stage biopharmaceutical company and a provider of therapies for the sports medicine and severe burn care markets. It markets cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane); Epicel (cultured epidermal autografts); and NexoBrid. The Company operates its business in the U.S. in one reportable segment; the research, product development, manufacture, and distribution of cellular therapies and specialty biologics for use in the treatment of specific conditions.